Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 6/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 4/20 | 1.00 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 1.00 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.72 |
| ▸ | ARRB1 | P49407 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nalorphine SCHEMBL17771837 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12030798 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL14124636 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL16015635 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12230555 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL12091243 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL38920 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL19199030 | 1.00 | OPRM1 (1.00) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL1883694 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 | |
| Nalorphine SCHEMBL149571 | 0.99 | OPRM1 (0.98) | OPRM1OPRK1OPRD1SIGMAR1MRGPRX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120282255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE | SUMMIT BIOSCIENCES, INC. | 2012-11-08 | — | — | US | claimed |
| WO-1997047293-A1 | USE OF PREPARATIONS CONTAINING OPIATE ANTAGONISTS AND AGONISTS FOR THE PREVENTION AND THERAPEUTIC TREATMENT OF MIGRAINES | VIVA DIAGNOSTIKA DIAGNOSTISCHE PRODUKTE GMBH (DE) | 1997-12-18 | — | — | WO | claimed |
| EP-0154639-A1 | PHARMACEUTICAL COMPOSITIONS HAVING APPETITE REDUCING ACTIVITY AND A PROCESS FOR THEIR PREPARATION. | BALKANYI IVAN (HU) | 1985-09-18 | — | — | EP | claimed |
| WO-1985000970-A1 | PHARMACEUTICAL COMPOSITIONS HAVING APPETITE REDUCING ACTIVITY AND A PROCESS FOR THEIR PREPARATION | BALKANYI IVAN | 1985-03-14 | — | — | WO | claimed |
| US-20120282255-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ALCOHOLISM AND ALCOHOL DEPENDENCE | SUMMIT BIOSCIENCES, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| US-20030130322-A1 | Biaryl ether derivative as opiod antagonist | PFIZER INC. | 2003-07-10 | — | — | US | disclosed |
| EP-1262196-A2 | Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence | Pfizer Products Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130322-A1 | Biaryl ether derivative as opiod antagonist | OPRM1, OPRD1, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 2/4885 |
| US-20040162316-A1 | Combination treatment for alcoholism and alcohol dependence | OPRM1, SLC6A2, OPRK1 | OPRM1 1/4885OPRK1 3/4885OPRD1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.